More Than 450 Companies Drive Speed to Market with Veeva RIM
Veeva Systems (NYSE:VEEV) announced significant adoption of its Regulatory Information Management (RIM) platform, now used by over 450 companies, including 19 of the top 20 biopharmas. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to enhance multi-health authority platform integration.
The platform's continuous publishing feature through Veeva Submissions Publishing is being utilized by more than 85 organizations to accelerate submission timelines. Accumulus's network connects over 70 regulatory agencies worldwide, while DNAnexus integration aims to improve inter-agency collaboration for faster product approvals.
Veeva Systems (NYSE:VEEV) ha comunicato una significativa adozione della sua piattaforma Regulatory Information Management (RIM), ora impiegata da oltre 450 aziende, compresa la maggior parte delle top 20 biopharma (19 su 20). L'azienda ha stretto partnership strategiche con Accumulus Technologies e DNAnexus per potenziare l'integrazione della piattaforma tra pi霉 autorit脿 sanitarie.
La funzione di pubblicazione continua tramite Veeva Submissions Publishing 猫 utilizzata da oltre 85 organizzazioni per accelerare i tempi di sottomissione. La rete di Accumulus collega pi霉 di 70 agenzie regolatorie nel mondo, mentre l'integrazione con DNAnexus punta a migliorare la collaborazione inter-agenzia per ottenere approvazioni di prodotto pi霉 rapide.
Veeva Systems (NYSE:VEEV) anunci贸 una adopci贸n significativa de su plataforma Regulatory Information Management (RIM), que ya utiliza m谩s de 450 empresas, incluidas 19 de las 20 principales biofarmac茅uticas. La compa帽铆a ha establecido alianzas estrat茅gicas con Accumulus Technologies y DNAnexus para mejorar la integraci贸n de la plataforma entre m煤ltiples autoridades sanitarias.
La funci贸n de publicaci贸n continua mediante Veeva Submissions Publishing est谩 siendo empleada por m谩s de 85 organizaciones para acelerar los plazos de presentaci贸n. La red de Accumulus conecta a m谩s de 70 agencias regulatorias en todo el mundo, mientras que la integraci贸n con DNAnexus busca potenciar la colaboraci贸n entre agencias para acelerar las aprobaciones de productos.
Veeva Systems (NYSE:VEEV)電� 鞛愳偓鞚� 攴滌牅 鞝曤炒 甏�毽�(RIM) 頂岆灚韽检澊 韥矊 頇曥偘霅橃柎 順勳灛 450臧� 鞚挫儊 旮办梾鞐愳劀 靷毄 欷戩澊氅� 靸侅渼 20臧� 氚旍澊鞓れ牅鞎届偓 欷� 19瓿踌澊 韽暔霅滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� Accumulus Technologies 氚� DNAnexus鞕� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 觳搓舶頃� 雼り赴甏� 氤搓贝 攴滌牅 雼龟淡 臧� 頂岆灚韽� 韱淀暕鞚� 臧曧檾頃橁碃 鞛堨姷雼堧嫟.
Veeva Submissions Publishing鞚� 韱淀暅 鞐办啀 瓴岇嫓 旮半姤鞚� 85臧� 鞚挫儊鞚� 臁办鞐愳劀 鞝滌稖 鞚检爼鞚� 雼稌頃橁赴 鞙勴暣 頇滌毄霅橁碃 鞛堨姷雼堧嫟. Accumulus鞚� 雱ろ姼鞗岉伂電� 鞝� 靹戈硠 70臧� 鞚挫儊鞚� 攴滌牅 旮瓣磤鞚� 鞐瓣舶頃橂┌, DNAnexus 韱淀暕鞚� 旮瓣磤 臧� 順戩梾鞚� 臧滌劆頃� 鞝滍拡 鞀轨澑 靻嶋弰毳� 雴掛澊電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Veeva Systems (NYSE:VEEV) a annonc茅 une adoption significative de sa plateforme Regulatory Information Management (RIM), d茅sormais utilis茅e par plus de 450 entreprises, dont 19 des 20 premi猫res biopharmas. L'entreprise a nou茅 des partenariats strat茅giques avec Accumulus Technologies et DNAnexus pour renforcer l'int茅gration de la plateforme entre plusieurs autorit茅s sanitaires.
La fonctionnalit茅 de publication continue via Veeva Submissions Publishing est utilis茅e par plus de 85 organisations pour acc茅l茅rer les d茅lais de soumission. Le r茅seau d'Accumulus relie plus de 70 agences r茅glementaires dans le monde, tandis que l'int茅gration avec DNAnexus vise 脿 am茅liorer la collaboration inter-agences pour des approbations de produits plus rapides.
Veeva Systems (NYSE:VEEV) gab bekannt, dass seine Regulatory Information Management (RIM)-Plattform nun umfangreich eingef眉hrt ist und von 眉ber 450 Unternehmen genutzt wird, darunter 19 der Top-20-Biopharmaunternehmen. Das Unternehmen hat strategische Partnerschaften mit Accumulus Technologies und DNAnexus geschlossen, um die plattform眉bergreifende Integration zwischen mehreren Gesundheitsbeh枚rden zu verbessern.
Die fortlaufende Ver枚ffentlichungsfunktion 眉ber Veeva Submissions Publishing wird von mehr als 85 Organisationen genutzt, um Einreichungszeiten zu beschleunigen. Das Netzwerk von Accumulus verbindet 眉ber 70 Zulassungsbeh枚rden weltweit, w盲hrend die DNAnexus-Integration die Zusammenarbeit zwischen Beh枚rden verbessern und damit Produktzulassungen beschleunigen soll.
- Strong market adoption with over 450 companies using Veeva RIM, including 19 of top 20 biopharmas
- Strategic partnerships with Accumulus Technologies and DNAnexus enhance platform capabilities
- 85+ organizations using continuous publishing feature for improved efficiency
- Access to Accumulus's network of 70+ regulatory agencies worldwide
- None.
Insights
Veeva's RIM platform reaches 450 customers including top biopharmas, expanding market dominance through strategic partnerships and enhanced capabilities.
Veeva Systems has achieved a significant milestone with its Regulatory Information Management (RIM) platform now being used by more than 450 companies, including 19 of the top 20 biopharma organizations. This level of adoption demonstrates Veeva's continued dominance in the life sciences regulatory technology space.
The announcement highlights two strategic partnerships that strengthen Veeva's ecosystem: Accumulus Technologies, which connects to over 70 regulatory agencies worldwide, and DNAnexus, which offers Trusted Regulatory Spaces for data sharing. These integrations create a powerful network effect that reinforces Veeva's platform value proposition while addressing a critical pain point in regulatory submissions - connectivity with health authorities.
Veeva's continuous publishing functionality, now used by over 85 organizations, represents an important operational efficiency gain for pharmaceutical companies by reducing rework and bottlenecks in the submission process. This directly impacts speed-to-market for new treatments, a crucial competitive advantage in the pharmaceutical industry.
As part of Veeva's broader Development Cloud ecosystem, the RIM platform benefits from integration across clinical, quality, regulatory, and safety functions. This unified approach offers customers significant operational efficiencies compared to managing these functions through disparate systems.
The continued expansion of Veeva's regulatory platform solidifies their position as the leading provider of cloud solutions for life sciences regulatory affairs, enhancing their recurring revenue streams and competitive moat in this specialized enterprise software category.
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities
"Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, Veeva RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment," said Marc Gabriel, vice president, regulatory at Veeva.
Companies using Veeva RIM applications can streamline processes across all steps of the regulatory lifecycle. With , more than 85 organizations are using continuous publishing to reduce rework and remove bottlenecks, accelerating submission timelines.
"Our strategic partnership will connect the Accumulus platform and Veeva RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster," said Francisco Nogueira, CEO of Accumulus Technologies.
"Integrating DNAnexus Trusted Regulatory Spaces (TRS) and Veeva RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals," said Thomas Laur, CEO of DNAnexus.
Veeva RIM streamlines global regulatory processes on a single, cloud-based platform. It is part of , the technology foundation for product development across clinical, quality, regulatory, and safety. To learn more about Veeva RIM, visit .
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a , Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit .
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find听听(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at听.
Contact:
Elizabeth McGrane
Veeva Systems
[email protected]听
View original content to download multimedia:
SOURCE Veeva Systems
FAQ
How many companies are currently using Veeva RIM platform?
What new partnerships has Veeva Systems (VEEV) announced for RIM platform?
How many organizations use Veeva Submissions Publishing for continuous publishing?
What is the reach of Accumulus Technologies' regulatory network for Veeva RIM users?
What is Veeva RIM's role in the Veeva Development Cloud?
